Top 5 RSV Manufacturers

Published: November 2025

Respiratory Syncytial Virus (RSV) is an omnipresent virus that mainly impacts the lower respiratory system, resulting in infectious illnesses. Although it is primarily associated with infections in infants and older adults, it also presents considerable risks to people with weakened immune systems. It is important to note that RSV is acknowledged as a contagious respiratory pathogen that frequently results in serious illness and deaths, thus contributing to a significant increase in both economic and health-related burdens globally.

According to a report by the World Health Organization, approximately 33 million new cases of RSV infections are documented each year in children below five years old globally. This situation is mainly due to the lack of effective medical treatments for RSV infections. At present, there are various preventive options, including over-the-counter medications, nasal sprays, and humidifiers; however, these methods have proven inadequate as they only address symptoms. To address these shortcomings, RSV vaccines have emerged as a viable alternative, offering safe, targeted, and effective treatment options.

Considering ongoing research and an increasing number of clinical trials aimed at RSV treatment, the global market for RSV vaccines is expected to see more approvals of effective vaccines soon, ultimately contributing to better public health outcomes. Additionally, due to the rapid growth in the vaccines market, the demand for effective RSV vaccines is projected to increase soon, creating profitable opportunities for stakeholders in this field.

Roots Analysis has conducted an exhaustive study on RSV Vaccine Market featuring the current market landscape and future opportunity for the companies engaged in healthcare, over a span of next 10 years.

Top Five Leading RSV Manufacturers

Icosavax
Moderna
Pfizer
GlaxoSmithKline
Sanofi

Precision Medicine Oncology Companies

Interested in exploring all ~70 players offering RSV vaccines, along with their recent initiatives?

Discover Below the Details of Top 5 RSV Manufacturers

Let us dive deep into the details of the top 5 RSV manufacturers. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

**1. Icosavax (A company of AstraZeneca)**

Company Overview

Icosavax a biotechnology company which was acquired by AstraZeneca in 2024, aims to develop innovative vaccines and other therapeutic products. Icosavax was founded with the mission of addressing public health issues through the development of a wide range of vaccines, such as RSV vaccine. The proprietary VLP technology developed by Icosavax allows for the provision of safety and efficacy of vaccines and induce robust immune responses. The company is focused on conducting research and development efforts to support its commitment for improved healthcare outcomes and the reduction of complications from RSV infections, particularly among high-risk populations. While continuing its ongoing clinical trials, Icosavax has the potential to offer therapeutic solutions to protect global public health by combating RSV infections.

List of Parameter Including Stage of Development, Route of Administration, Type of Vaccine, Type of Protein Targeted, Type of Immunization and Target Patient Population

The section provides information on various parameters like stage of development by Icosavax, along with details on the route of administration, type of vaccine, type of protein targeted, type of immunization and target patient population dedicated to RSV manufacturing.

Stage of Development: Phase II
Route of Administration: Intramuscular
Type of Vaccine: Subunit / Viral-like-Particle (VLP) Vaccine
Type of Protein Targeted: Protein F
Type of Immunization: Active
Target Patient Population: Elderly Individuals

Recent Developments

In February 2024, AstraZeneca has completed the USD 1.1 bn acquisition of Icosavax, integrating its innovative RSV/hMPV VLP vaccine candidate IVX-A12 into AstraZeneca’s late-stage pipeline; Icosavax shares will be delisted and company registration terminated.

2. Moderna

Company Overview

Moderna is a pioneering biotechnology company known for its role in developing innovative treatments and vaccines using messenger RNA (mRNA) technology. Since its establishment, Moderna has focused on creating transformative medicines for a variety of diseases, with a strong emphasis on infectious diseases, oncological disorders, cardiovascular disorders and autoimmune disorders. The company has achieved remarkable historical milestones by developing safe and effective mRNA vaccine and therapeutics for both influenza and COVID-19. In addition, the company is actively advancing its RSV vaccine, aiming to provide effective protection against the virus. Through these initiatives, Moderna is committed to address the critical healthcare challenges and improve patient outcomes worldwide.

List of Parameter Including Stage of Development, Route of Administration, Type of Vaccine, Type of Protein Targeted, Type of Immunization and Target Patient Population

The section provides information on various parameters like stage of development by Moderna, along with details on the route of administration, type of vaccine, type of protein targeted, type of immunization and target patient population dedicated to RSV manufacturing.

Stage of Development: Approved
Route of Administration: Intramuscular
Type of Vaccine: mRNA Vaccine
Type of Protein Targeted: Protein F
Type of Immunization: Active
Target Patient Population: Elderly Individuals

Recent Developments

In September 2025, Moderna has officially opened its Innovation and Technology Centre in Harwell, Oxfordshire, the UK's first facility to manufacture mRNA vaccines domestically, producing up to 100 million doses annually to support NHS seasonal vaccination and pandemic readiness, while also advancing research into mRNA applications for diseases like cancer and rare disorders as part of a strategic ten-year UK partnership.

To know more about the recent initiatives of Moderna and other RSV manufacturers, access full report.

3. Pfizer

Company Overview

Pfizer is a leading global biopharmaceutical company renowned for its research-driven approach in healthcare. The firm claims to develop a wide range of medicines and vaccines across multiple therapeutic areas, including oncology, cardiology, immunology, and infectious diseases. Further, the company operates through two primary commercial segments, namely Biopharma and Business Innovation (contract development and manufacturing segment). Notably, the company is also committed to sustainability and corporate social responsibility, aimed at improving health outcomes globally, while addressing environmental challenges. Pfizer, with its robust history of innovation, is actively advancing the development of new vaccines, including the RSV vaccine, through cutting-edge research and technological advancements. These efforts reflect Pfizer’s broader commitment to addressing serious infectious diseases and improving the health of vulnerable populations worldwide.

List of Parameter Including Stage of Development, Route of Administration, Type of Vaccine, Type of Protein Targeted, Type of Immunization and Target Patient Population

Stage of Development: Approved
Route of Administration: Intramuscular
Type of Vaccine: Subunit / Viral-like-Particle (VLP) Vaccine
Type of Protein Targeted: Protein F
Type of Immunization: Active, Passive
Target Patient Population: Elderly Individuals, Pregnant Individuals

Recent Developments

In April 2025, Pfizer announced that the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation to include ABRYSVO, for adults aged 50-59 at increased risk of RSV-associated lower respiratory tract disease. ABRYSVO had been approved by the FDA in October 2024 for adults 18-59 at increased risk. The ACIP vote aimed to protect this at-risk population with a single vaccine dose, expanding on previous approvals for older adults.

4. GlaxoSmithKline

Company Overview

GlaxoSmithKline (GSK), a global healthcare company focused on the development of novel vaccines and specialty drugs aimed at improving the overall public health. The firm is also focused on the integration of science, human genetic and advanced technologies to develop vaccines and drugs for various therapeutic areas, including infectious diseases, oncological disorders, immunological disorders and chronic diseases. Furthermore, the company has been exploring innovative vaccine solutions and strategies to elicit strong immune responses against severe infectious disorders, including RSV. With a commitment to public health, GSK's efforts in the RSV vaccine domain reflect its dedication to address the critical health challenges and improving the overall outcomes.

List of Parameter Including Stage of Development, Route of Administration, Type of Vaccine, Type of Protein Targeted, Type of Immunization and Target Patient Population

Stage of Development: Approved
Route of Administration: Intramuscular
Type of Vaccine: Subunit / Viral-like-Particle (VLP) Vaccine
Type of Protein Targeted: Protein F
Type of Immunization: Active
Target Patient Population: Elderly Individuals

Recent Developments

In March 2025, GSK presented 17 abstracts at the 13th International RSV Symposium in Brazil, highlighting new data on its RSV vaccine Arexvy, global disease burden, vaccine efficacy, and cost-effectiveness, reinforcing its commitment to advancing adult RSV prevention worldwide.

5. Sanofi

Company Overview

Sanofi specializes in research, development, manufacturing and marketing of a wide range of pharmaceutical products. The company primarily focuses on developing solutions for therapeutic areas, such as oncology, immunology, neurology, inflammation and other rare diseases. With a strong commitment to research and development, Sanofi has made significant advancements in addressing infectious diseases, including respiratory syncytial virus (RSV). By enhancing scientific knowledge and improving vaccine accessibility, Sanofi is at the forefront to combat RSV and improve public health outcomes worldwide. Sanofi's future viewpoint focuses on transforming the company into a biopharma firm, by improving its research and development capabilities and optimizing their business models.

List of Parameter Including Stage of Development, Route of Administration, Type of Vaccine, Type of Protein Targeted, Type of Immunization and Target Patient Population

Stage of Development: Phase III
Route of Administration: Intramuscular
Type of Vaccine: Live Attenuated Vaccine
Type of Protein Targeted: Undisclosed
Type of Immunization: Active
Target Patient Population: Infants / Children

Recent Developments

In June 2025, Sanofi, with AstraZeneca, had tripled Beyfortus production capacity and expanded manufacturing sites to ensure broad early Q3 shipments ahead of the 2025–2026 RSV season, meeting last year’s total supply and reinforcing confidence in widespread infant protection.

What About Other RSV Manufacturers Around the World?

The above article features the top five RSV manufacturers selected from a pool of around 70 manufacturers that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: